Connect with us

Biotech

Lanzadera Increases its Commitment to the Health Sector and Incorporates Nine Companies

Among the companies selected by Lanzadera there are projects related to the diagnosis of sepsis, pathologies related to muscles and skeletons or those that investigate skin diseases. Since its founding in 2013 to date, Lanzadera has boosted more than a thousand companies and provided more than €21 million in loans. Sanidae has also been added to the health list

Published

on

Lanzadera raises its bet on the health sector. The accelerator promoted by the president of Mercadona, Juan Roig, has selected Healz, Ibions, Loop Diagnostics, Maternify, Neil, Onalabs, Sanidae, Startquake, and Ysium as companies to support in its latest call, which was announced this Monday and reported by ABC. Lanzadera has selected 120 new teams this time. The companies are innovating in areas such as health, food, education, mobility, and circular economy.

Healz solves problems of nutrition, performance, sleep, stress, and fatigue through accurate and personalized measurements. Loop Diagnostics has developed a new sepsis diagnostic test that is three times more effective and ten times faster than other tools available on the market. Loop Diagnostics has opened a €1 million round aimed at funding the market launch of its biomarker.

Maternify is a network of home-based, online maternity professionals that allows you to receive medical care in less than two hours. Neil, on the other hand, helps through artificial intelligence (AI) algorithms to have a more accurate diagnosis of musculoskeletal pathologies and faster rehabilitation.

Another company that has made itself known is Onalabs. The company develops products capable of reading, interpreting, and translating skin into valuable health information. Last April, the company closed its first round of funding raising €1.2 million. The round was conducted through the crowdfunding platform Capital Cell. Onalabs will allocate the resources to continue the technological development and certification of its medical devices. These meters are focused on monitoring chronic patients, athletes and people with type I and II diabetes.

If you want to read more on the subject and to find the most important business news of the day, download for free our companion app Born2Invest.

SEE ALSO  Titanium 3D printing lessens space exploration costs

Lanzadera also promotes food, education, mobility, and circular economy projects

Sanidae, a platform for home health services that connects health professionals and patients, has also been added to the health list. Startquake, meanwhile, combines AI, massive proteomics, and biometric markers that allow health monitoring in a simple way, at home, and through an app.

Ysium Medical designs and develops innovative medical devices that, in collaboration with healthcare companies and established sales channels, reach the market. These nine companies join the last ones selected in May: FisioReact, Dynamics VR, and Farma Leaders.

Since its founding in 2013 to date, Lanzadera has boosted more than a thousand companies and provided more than €21 million in loans. Currently, more than 300 companies are receiving support from Lanzadera at its facilities in the Marina de Valencia.

The selected companies can receive grants starting from one thousand euros to the financing of €500,000, depending on the needs of each one. Lanzadera has assigned 120 companies to one of the four phases that make up the program, depending on their degree of maturity.

The four stages are: the “Scale Up” phase, for mature start-ups with a proven and profitable model; the “Growth” phase, for companies with potential but seeking faster growth; the “Tractio” phase, focused on start-ups in the early stages; and the “Start” phase, for entrepreneurs who are still shaping their project.

__

(Featured image by Online Marketing via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Desmond O’Flynn believes in minimalism and the power of beer. As a young reporter for some of the largest national publications, he has lived in the world of finance and investing for nearly three decades. He has since included world politics and the global economy in his portfolio. He also writes about entrepreneurs and small businesses, as well as innovation in fintech, gambling, and cannabis industries.